Literature DB >> 28861767

Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis.

Zanfeng Wang1, Tingwei Liu2.   

Abstract

Vascular endothelial growth factor (VEGF) family members play critical and complex roles in the regulation of cancer vascularization and metastasis. The exact molecular control of lung cancer metastasis by VEGF family members is not completely understood. Here, we showed that specimens from non-small cell lung cancer (NSCLC) contained significantly higher levels of placental growth factor (PlGF) than paired non-cancer tissue (p < 0.05, N = 25). Moreover, higher levels of PlGF were detected in NSCLC specimens from the patients who had distal metastases than those who had not. High-PlGF levels appeared to be associated with poor patient survival. In vitro, PlGF dose-dependently increased the ratio of pro-angiogenic VEGF isoform (VEGF165) versus anti-angiogenic VEGF isoform (VEGF165b), seemingly through induction of expression of splicing regulatory factor SRp40, resulting in the enhancement of the cancer cell metastatic potential. Higher levels of SRp40 were detected in NSCLC specimens, compared to paired non-cancer tissue (p < 0.05, N = 25). Finally, a strong correlation was detected between the levels of PlGF and SRp40 in NSCLC specimens (r = 0.83, p < 0.0001, N = 25). Together, these data suggest that PlGF may increase NSCLC metastasis through SRp40-mediated mRNA splicing of VEGF.

Entities:  

Keywords:  Isoform splicing; Non-small cell lung cancer (NSCLC); Placental growth factor (PlGF); SRp40; Vascular endothelial growth factor (VEGF)

Mesh:

Substances:

Year:  2017        PMID: 28861767     DOI: 10.1007/s11010-017-3145-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

1.  Inhibition of ocular neovascularization by co-inhibition of VEGF-A and PLGF.

Authors:  Xiaochuan Huo; Youxiang Li; Yuhua Jiang; Xiaoyun Sun; Lixue Gu; Wenshi Guo; Dapeng Sun
Journal:  Cell Physiol Biochem       Date:  2015-03-26

Review 2.  Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.

Authors:  Jonathan Welti; Sonja Loges; Stefanie Dimmeler; Peter Carmeliet
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

3.  Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.

Authors:  Christian Fischer; Bart Jonckx; Massimiliano Mazzone; Serena Zacchigna; Sonja Loges; Lucia Pattarini; Emmanuel Chorianopoulos; Laurens Liesenborghs; Marta Koch; Maria De Mol; Monica Autiero; Sabine Wyns; Stephane Plaisance; Lieve Moons; Nico van Rooijen; Mauro Giacca; Jean-Marie Stassen; Mieke Dewerchin; Desire Collen; Peter Carmeliet
Journal:  Cell       Date:  2007-11-02       Impact factor: 41.582

Review 4.  HIFs, angiogenesis, and cancer.

Authors:  Yongzhi Yang; Mingjuan Sun; Lianghua Wang; Binghua Jiao
Journal:  J Cell Biochem       Date:  2013-05       Impact factor: 4.429

5.  p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis.

Authors:  Raquel Díaz; Cristina Peña; Javier Silva; Yolanda Lorenzo; Vanesa García; José M García; Antonio Sánchez; Pablo Espinosa; Rosario Yuste; Félix Bonilla; Gemma Domínguez
Journal:  Int J Cancer       Date:  2008-09-01       Impact factor: 7.396

6.  Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

Authors:  A Takahashi; H Sasaki; S J Kim; K Tobisu; T Kakizoe; T Tsukamoto; Y Kumamoto; T Sugimura; M Terada
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

7.  The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.

Authors:  Es Rennel; E Waine; H Guan; Y Schüler; W Leenders; J Woolard; M Sugiono; D Gillatt; Es Kleinerman; Do Bates; Sj Harper
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

8.  TIPE2 suppresses angiogenesis and non-small cell lung cancer (NSCLC) invasiveness via inhibiting Rac1 activation and VEGF expression.

Authors:  Zequn Li; Chun Guo; Xianglan Liu; Chengjun Zhou; Faliang Zhu; Xiaoyan Wang; Qun Wang; Yongyu Shi; Jianing Wang; Wei Zhao; Lining Zhang
Journal:  Oncotarget       Date:  2016-09-20

9.  Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.

Authors:  Dawid G Nowak; Jeanette Woolard; Elianna Mohamed Amin; Olga Konopatskaya; Moin A Saleem; Amanda J Churchill; Michael R Ladomery; Steven J Harper; David O Bates
Journal:  J Cell Sci       Date:  2008-10-15       Impact factor: 5.285

10.  Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation.

Authors:  Yan Li; Yanmei Wang; Kai Niu; Xiewan Chen; Liqin Xia; Dingxi Lu; Rui Kong; Zhengtang Chen; Yuzhong Duan; Jianguo Sun
Journal:  Oncotarget       Date:  2016-10-25
View more
  1 in total

1.  PlGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/β-catenin pathway.

Authors:  Wei Zhang; Yanwei Zhang; Wensheng Zhou; Fangfei Qian; Minjuan Hu; Ya Chen; Jun Lu; Yuqing Lou; Baohui Han
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.